Novo Nordisk Total Long Term Liabilities 2010-2025 | NVO

Novo Nordisk total long term liabilities for the quarter ending March 31, 2025 were $16.157B, a 222.54% increase year-over-year.

  • Novo Nordisk total long term liabilities for 2024 were $15.193B, a 173.42% increase from 2023.
  • Novo Nordisk total long term liabilities for 2023 were $5.557B, a 6.55% increase from 2022.
  • Novo Nordisk total long term liabilities for 2022 were $5.215B, a 35.2% increase from 2021.

Novo Nordisk Total Long Term Liabilities 2010-2025 | NVO

  • Novo Nordisk total long term liabilities for 2024 were $15.193B, a 173.42% increase from 2023.
  • Novo Nordisk total long term liabilities for 2023 were $5.557B, a 6.55% increase from 2022.
  • Novo Nordisk total long term liabilities for 2022 were $5.215B, a 35.2% increase from 2021.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$796.4B
Johnson & Johnson (JNJ)$379.5B
AbbVie (ABBV)$306B
Roche Holding AG (RHHBY)$248.1B
Novartis AG (NVS)$234.2B
Merck (MRK)$196.7B
Sanofi (SNY)$128.6B
Pfizer (PFE)$125.6B
Bayer (BAYRY)$23.7B
Innoviva (INVA)$1.1B